Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01792050

Recruitment Status : Completed

First Posted : February 15, 2013

Last Update Posted : May 28, 2020

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Lumos Pharma ( NewLink Genetics Corporation )

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	July 1, 2016
Actual Study Completion Date :	July 7, 2017
Certification/Extension First Submitted :	February 22, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mariotti V, Han H, Ismail-Khan R, Tang SC, Dillon P, Montero AJ, Poklepovic A, Melin S, Ibrahim NK, Kennedy E, Vahanian N, Link C, Tennant L, Schuster S, Smith C, Danciu O, Gilman P, Soliman H. Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021 Jan 1;7(1):61-69. doi: 10.1001/jamaoncol.2020.5572. Erratum In: JAMA Oncol. 2021 Jan 1;7(1):140.

To Top